Actively Recruiting
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
Led by University of California, Davis · Updated on 2026-04-13
30
Participants Needed
1
Research Sites
94 weeks
Total Duration
On this page
Sponsors
U
University of California, Davis
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
CONDITIONS
Official Title
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-80 years with sickle cell disease confirmed by hemoglobin electrophoresis or high performance liquid chromatography
- Ability to provide written informed consent
- Ability to lie on a dual-energy X-ray absorptiometry (DXA) scanner
- Negative urine pregnancy test for those of childbearing potential at study entry
You will not qualify if you...
- Pregnant women
- Adults unable to consent
- Individuals who are not adults (infants, children, teenagers)
- Prisoners
- Hospitalization for any cause within 2 weeks prior to study entry
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UC Davis Comprehensive Cancer Center
Sacramento, California, United States, 95817
Actively Recruiting
Research Team
L
Leyla Y Teos, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here